ISPOR 2023

Join EVERSANA and global healthcare leaders as they convene at ISPOR 2023, the leading global conference for Health Economics and Outcomes Research (HEOR).

Our Value & Evidence and Data & Analytics experts will be onsite to discuss how we use a variety of analytics, evidence generation, and evidence synthesis activities to help support market access and reimbursement for pharmaceutical and medical devices.

Schedule a meeting with one of our experts to discuss your business needs and visit us in Booth #1130.

EVERSANA’s 2023 Poster Presentations

We are proud to present several posters at this year’s ISPOR conference. Check back soon for more information on our poster presentations.

Monday, May 8, 2023 | Poster Session 1 

•  MT1: Challenges and Opportunities with Quantifying Comprehensive Health Economics of Diagnostic Imaging Modalities Using Radiopharmaceuticals: A Case Study in Coronary Artery Disease
  Ferko N¹, Priest S¹, Almuallem L¹, Oliva Ramirez A¹, Szabo E², Cabra HA^{2
  1}EVERSANA, Burlington, ON, Canada, ²GE HealthCare, Miami, FL, USA 
• MT3: Delphi Panel on the Recommended Use of the Cue COVID-19 at Home Diagnostic Test
  Tsay D¹, Pastor L², Whitney S³, Bourque M², Duggal N^{1
  1}Cue Health, San Diego, CA, USA, ²EVERSANA, Burlington, ON, Canada, ³EVERSANA, Oakville, ON, Canad
• MSR21: Impact of Correlated Outcomes in Probabilistic Sensitivity Analyses When Treatment Effects Are Derived from a Network Meta-Analysis
  Disher T¹, Szafranski K^{2
  1}EVERSANA, West Porters Lake, NS, Canada, ²EVERSANA, Burlington, ON, Canad
• MSR23: Improving the Interpretability of Ordinal Endpoints in NMAs
  Disher T
  EVERSANA, West Porters Lake, NS, Canad

Monday, May 8, 2023 | Poster Session 2

• RWD44: Use of Real-World Data for Hard-to-Identify Patient Population: Methodology and a Case Study
  Cyhaniuk A¹, Shokoohi M1
  ¹EVERSANA, Burlington, ON, Canada, ²EVERSANA, Yardley, PA, USA
• C071: The impact of socioeconomic status (SES), insurance type, and treatment facility on survival in metastatic prostate cancer (mPC): a systematic literature review (SLR) of social determinants of health (SDOH) 
  Freedland S¹, Hall A², Lansing A², Rai M², Rosta E², Niyazov A³, Nazari J³, Samjoo I², Arondekar B^{4 
  1}Cedars-Sinai Medical Center, Los Angeles, CA, USA, ²EVERSANA, Burlington, ON, Canada, ³Pfizer Inc., New York, NY, USA, ⁴Pfizer Inc., Collegeville, PA, USA
• MSR45: Identifying Longitudinal Treatment Effect Trajectories Using Flexible Outcome Modeling and Clustering 
  Disher T, Gotera K, Ellis J 
  EVERSANA, Burlington, ON, Canada

Tuesday, May 9, 2023 | Poster Session 3 

• MSR50: A Practical Method for Determining the Optimal Allocation between Computation Time and Accuracy in Probabilistic Patient-Level Microsimulation Models
  Szafranski K¹, Disher T², Brown S^{1
  1}EVERSANA, Burlington, ON, Canada, ²EVERSANA, West Porters Lake, NS, Canada 
• SA38: Approaches to Comparing Treatments from Meta-Analyses of Single-Arm Studies from a Systematic Literature Review: Case Example of Non-Surgical Technologies for Treatment of Lung Cancer 
  Naghi A¹, Wright G¹, Disher T², Laidlaw A¹, Kalsekar I³, Zhou M³, Ghosh S⁴, Ferko N^{1 
  1}EVERSANA, Burlington, ON, Canada, ²EVERSANA, West Porters Lake, NS, Canada, ³Johnson & Johnson, New Brunswick, NJ, USA, ⁴Ethicon Inc, Cincinnati, OH, USA 

Tuesday, May 9, 2023 | Poster Session 4 

• EE345: Strengths and Limitations of Different Costing Approaches Used for Hospital Budget Impact Models: Application to Imaging Guidance in Left Atrial Appendage Occlusion Procedures
  Ferko N¹, Mohr BA², Patel BP¹, Dobrin A^{1
  1}EVERSANA, Burlington, ON, Canada, ²Philips, Phoenix, AZ, USA 
• PCR169: A Systematic Literature Review (SLR) of Health State Utility Values (HSUV) in Metastatic Castration-Resistant Prostate Cancer (MCRPC)
  Castro E¹, Debnath A², Olsen C², Craigie S², Nazari J³, Niyazov A³, Samjoo I^{2 
  1}Hospital Universitario 12 de Octubre, Madrid, Spain, ²EVERSANA, Burlington, ON, Canada, ³Pfizer Inc., New York, NY, USA 

Wednesday, May 10, 2023 | Poster Session 5 

• CO226: Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Multiple Myeloma in the US: Real-World Evaluation of Patient Characteristics and Treatment Patterns
  Pfeffer D², Cyhaniuk A¹, Lussier C1, Nayak P³, Liu R¹, Prasad S¹, Sehgal P^{1
  1}EVERSANA, Yardley, PA, USA, ²EVERSANA Life Sciences Inc., Milwaukee, WI, USA, ³EVERSANA, Atlanta, GA, US
• EE460: A Budget Impact Model to Evaluate the Economic Impact of Treating Walking Impairment in Chronic Stroke, A US Perspective
  Kane S¹, Jayawardena N¹, Bourque M¹, Lavanture J², Roberts H^{2 
  1}EVERSANA, Burlington, ON, Canada, ²MedRhythms, Portland, ME, US
• EPH246: Real-World Evaluation of Health Disparities in Treatment Patterns for Systemic Lupus Erythematosus
  Nayak P¹, Cyhaniuk A², Prasad S², Pfeffer D³, Shokoohi M^{4
  1}EVERSANA, Atlanta, GA, USA, ²Eversana, Yardley, PA, USA, ³EVERSANA Life Sciences Inc., Milwaukee, WI, USA, ⁴EVERSANA, Burlington, ON, Canada 
• CO227: An Updated Umbrella Review Comparing the Safety and Effectiveness of Femtosecond Laser-Assisted Cataract Surgery with Manual Cataract Surgery
  Pan SM¹, Ainslie-Garcia M², Ferko N², Hsiao CW¹, Cheng H^{1
  1}Alcon Vision LLC, Fort Worth, TX, USA, ²EVERSANA, Burlington, ON, Canada
• CO221: Efficacy and Safety of Personalized Topography-Guided-Lasik Laser Refractive Correction: A Targeted Literature Review
  Zhang J¹, Hsiao CW², Kambli A³, Persaud E^{3 
  1}Alcon Vision, Fort Worth, TX, USA, ²Alcon Inc., Fort Worth, TX, China, ³EVERSANA, Burlington, ON, Canada
• EE558: Key Methodological Considerations for Developing Cost-Offset Budget Impact Models for a Range of Medical Technologies and Cost Perspectives in Ophthalmology
  Ferko N¹, Persaud E¹, Ainslie-Garcia M¹, Wright G¹, Son D¹, Cheng H^{2
  1}EVERSANA, Burlington, ON, Canada, ²Alcon Vision LLC, Fort Worth, TX, USA
• MSR100: Validation of a Mixed Model for Repeated Measures Approach to Including Trials with Varying Follow-up in Indirect Treatment Comparisons of Long-Term Outcomes
  Walsh S¹, Disher T^{2 
  1}EVERSANA, Burlington, Canada, ²EVERSANA, Burlington, ON, Canada
• MSR107: Assessment of the Power of ITCs to Detect Minimally Important Treatment Effects in Subsequent Head-to-Head Trials
  Disher T
  EVERSANA, West Porters Lake, NS, Canada
• MSR109: When Can an Unanchored Analysis be More Credible Than an Anchored One?
  Disher T¹, Spin P², Bonner A^{3
  1}EVERSANA, West Porters Lake, NS, Canada, ²EVERSANA, Sydney, NS, Canada, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
• EPH246: Real-World Evaluation of Health Disparities in Treatment Patterns for Systemic Lupus Erythematosus
  Nayak P¹, Cyhaniuk A², Prasad S², Pfeffer D³, Shokoohi M^{4
  1}EVESANA, Atlanta, GA, USA, ²EVERSANA, Yardley, PA, USA, ³EVERSANA Life Sciences Inc., Milwaukee, WI, USA, ⁴EVERSANA, Burlington, ON, Canada

Additional Accepted Posters
The following EVERSANA abstracts were accepted but will not be presented during ISPOR 203 poster sessions. Stop by booth #1130 to learn more about the following submissions.

• MSR25: A Simple Template for Interactive Visualization of Complex NMAs
  Disher T
  EVERSANA, West Porters Lake, NS, Canada
• MSR22: Comparison of Approaches to Estimating Achievement of MCIDs of Continuous and Binary Outcomes in Primary Data and ITCs without Access to IPD
  Disher T
  EVERSANA, West Porters Lake, NS, Canad
• MSR48: Comparison of Two Approaches to Early ITC Feasibility without Outcome Data 
  Disher T 
  EVERSANA, West Porters Lake, NS, Canada 
• MSR86: Proportional Odds and MCIDs of Continuous Outcomes – Visual Assessments and Flexible Models
  Disher T
  EVERSANA, West Porters Lake, NS, Canada
• MSR90: Validation of MBNMA for Assessment of Time to Onset of Action
  Disher T
  EVERSANA, West Porters Lake, NS, Canada
• MSR67: The Impact of Power on the Interpretation of Results Subject to Publication Bias
  Disher T
  EVERSANA, West Porters Lake, NS, Canada

Our Latest Insights on Key Industry Topics

Check out our latest article authored by our team of experts or explore our library of publications to learn more about our RWE/HEOR efforts.

• Filling the Missing Spaces in Your Network Meta-Analysis: The Role of Surrogate Models
• Single-Arm Data: Turning Limitations into Strengths with Numbers
• Eight Key Strategic Considerations When Launching a Global Indirect Treatment Comparison Program for New Products
• Filling Evidence Gaps Through Consensus: Revisiting the Delphi Technique
• Case Study: Defining the Rare Disease Patient Journey to Support Commercialization of Therapy
• Use of Machine Learning to Accurately Size Market Potential and Optimize Sales and Marketing Resources
• Case Study: Optimizing Use of Field Reimbursement Managers
• Case Study: Waste Reduction through Packaging Optimization